Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity

Clinical and Experimental Obstetrics and Gynecology

Volumn 34, Issue 4, 2007, Pages 207-211

  Check, J H ^a,b   Sansoucie, L ^a   Chern, J ^a   Amadi, N ^a   Srivastava, M ^a   Larece, K ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

Cancer immunology; Natural killer cells; Progesterone receptor antagonist

Indexed keywords

MESSENGER RNA; MIFEPRISTONE;

ADVANCED CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER THERAPY; DOWN REGULATION; DRUG EFFECT; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LEUKEMIA CELL LINE; LONG TERM CARE; MENINGIOMA; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HORMONE ANTAGONISTS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; MICE; MIFEPRISTONE; PREGNANCY PROTEINS; PROGESTERONE; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SUPPRESSOR FACTORS, IMMUNOLOGIC;

EID: 38349115336     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Pence H., Petty W.M., Rocklin R.E.: "Suppression of maternal responsiveness to paternal antigens by maternal plasma". J. Immunol., 1975, 114, 525.
2. Szekeres-Bartho J., Kilar F., Falkay G. et al.: "Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis". Am. J. Reprod. Immunol. Microbiol., 1985, 9, 15.
3. Szekeres-Bartho J., Autran B., Debre P. et al.: "Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction". Cell. Immunol., 1989, 122, 281.
4. Szekeres-Bartho J., Kilar F., Falkay G. et al.: "The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes release a substance inhibiting cytotoxicity and prostaglandin synthesis". Am. J. Reprod. Microbiol., 1985, 9, 15.
5. Szekeres-Bartho J., Barakonyi A., Polgar B. et al.: "The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review". Am. J. Reprod. Immunol., 1999, 42, 44.
6. Szekeres-Bartho J., Csernus V., Hadnagy J.: "The blocking effect of progesterone on lymphocyte responsiveness is receptor-mediated". Biol. Immunol. Reprod., 1989, 15, 36.
7. Szekeres-Bartho J., Szekeres Gy, Debre P. et al.: "Reactivity of lymphocytes to a progesterone receptor specific monoclonal antibody". Cell. Immunol., 1990, 125, 273.
8. Chiu L., Nishimura M., Ishii Y. et al.: "Enhancement of the expression of progesterone receptor on progesterone treated lymphocyte after immunotherapy in unexplained recurrent spontaneous abortion". Am. J. Reprod. Immunol., 1996, 35, 552.
9. Szekeres-Bartho J., Weill B.J., Mike G. et al.: "Progesterone receptors in lymphocytes of liver-transplanted and transfused patients". Immunol. Lett., 1989, 22, 259.
10. Check J.H., Arwitz M., Gross J. et al.: "Lymphocyte immunotherapy (LI) increases serum levels of progesterone induced blocking factor (PIBF)". Am. J. Reprod. Immunol., 1997, 37, 17.
11. Faust Z., Laskarin G., Rukavina D. et al.: "Progesterone induced blocking factor inhibits degranulation of NK cells". Am. J. Reprod. Immunol., 1999, 42, 71.
12. Szekeres-Bartho J., Varga P., Retjsik B.: "ELISA test for detecting a progesterone-induced immunological factor in pregnancy serum". J. Reprod. Immunol., 1989, 16, 19.
13. Szekeres-Bartho J., Faust Zs., Varga P.: "The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes". Am. J. Reprod. Immunol., 1995, 34, 342.
14. Check J.H., Ostrzenski A., Klimek R.: "Expression of an immunomodulatory protein known as progesterone induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone supplemented women". Am. J. Reprod. Immunol., 1997, 37, 330.
15. Check J.H., Nazari P., Goldberg J., Yuen W., Angotti D.: "A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion". Med. Hypoth., 2001, 57, 337.
16. Srivastava M.D., Check J.H., Srivastava B.I.S., Thomas A.: "Inhibition of progesterone induced blocking factor (PIBF) in human leukemic cells by mifepristone (RU-486)". AACR Annual Meeting, Washington, DC, 2006 (poster #2188).
17. Check J.H., Sansoucie L., Chern J., Amadi N., Katz Y.: "The effect of treatment with a progesterone receptor antagonist on death from spontaneous lymphocytic leukemia in AKR/J mice". AACR Annual Meeting, Washington, DC, 2006 (poster no. 259).
18. Rosenberg S.A., Lotze M.T.: "Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes". Annu. Rev. Immunol., 1986, 4, 681.
19. Stevanovic S.: "Identification of tumour-associated T-cell epitopes for vaccine development". Nat. Rev. Cancer, 2002, 2, 514.
20. Dermime S., Armstrong A., Hawkins R.E., Stern P.L.: "Cancer vaccines and immunotherapy". Br. Med. Bull., 2002, 62, 149.
21. Acevedo H.F., Tang J.Y., Hartsock R.J.: "Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins". Cancer, 1995, 76, 1467.
22. Acevedo H.F., Longinotti S.M., Marquardt M.: "Expression of hCG, its subunits and fragments by human cultured cancer cells of the nervous system". Cancer Detect. Prevent., 1995, 19, 37.
23. Acevedo H.F., Campbell-Acevedo G.A., Buffo M.K., Krichevsky A.: "In vivo expression of membrane-associated human chorionic gonadotropin by cells isolated from cancerous human tissues". Proc. Am. Assoc. Cancer Res., 1994, 34, 27.
24. Klijn J.G., Setyono Han B., Foekens J.A.: "Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer". Steroids, 2000, 65, 825.
25. Romieu G., Maudelonde T., Ulmann A., Pujol H., Grenier J., Cavalie G. et al.: "The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial". Bull. Cancer, 1987, 74, 455.
26. Perrault D., Eisenhauer E.A., Pritchard K.I., Panasci L., Norris B., Vandenberg T. et al.: "Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study". J. Clin. Oncol., 1996, 14, 2709.
27. Bakker G.H., Setyono Han B., Portengen H., De Jong F.H., Foekens J.A., Klign J.G.: "Treatment of breast cancer with different antiprogestins: preclinical and clinical studies". J. Steroid. Biochem. Mol. Biol., 1990, 37, 789.
28. Grunberg S.M., Weiss M.H., Spitz I.M., Ahmadi J., Sadun A., Russell C.A. et al.: "Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone". J. Neurosurg., 1991, 74, 861.
29. Grunberg S.M.: "Role of antiprogestational therapy for meningiomas". Hum. Reprod., 1994, 9, 202.
30. Grunberg S.M., Rankin C., Townsend J., Ahamadi J., Feun L., Fredericks R. et al.: "Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma". In: American Society of Clinical Oncology. San Francisco, CA, 2001, 20.
31. Grunberg S.M., Weiss M.H., Spitz I.M., Zaretsky S., Kletzky O., Groshen S.: "Long-term treatment with the oral antiprogestational agent mifepristone (RU 486)". In: Salmon S.E. (ed.). Adjuvant Therapy of Cancer VII. Philadelphia, J.B. Lippincott, 1993, 55.
32. de Keizer R.J., Smit J.W.: "Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up". Eye, 2004, 18, 954.
33. Rocereto T.F., Saul H.M., Aikins J.A. Jr, Paulson J.: "Phase II study of mifepristone (RU486) in refractory ovarian cancer". Gynecol. Oncol., 2000, 77, 429.
34. Spitz I.M., Grunberg S.M., Chabbert-Buffet N., Lindenberg T., Gelber H., Sitruk-Ware R.: "Management of patients receiving long-term treatment with mifepristone". Fertil. Steril., 2005, 84, 1710.
35. Xiao B.L., von Hertzen H., Zhao H., Piaggio G.: "A randomized double-blind comparison of two single doses of mifepristone for emergency contraception". Hum. Reprod., 2002, 17, 3084.
36. von Hertzen H., Piaggio G., Ding J., Chen J., Song S., Bartfai G. et al.: "Low-dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial". Lancet, 2002, 360, 1803.
37. World Health Organization Task Force on Postovulatory Methods of Fertility Regulation: "Comparison of three single doses of mifepristone as emergency contraception: a randomized trial". Lancet, 1999, 353, 697.
38. Lui W.Y. et al.: "In vivo and in vitro growth stimulation of murine hepatoma cells by glucocorticoid". Anticancer Res., 2002, 22, 1413.
39. Nieman L.K., Chrousos G.P., Kellner C., Spitz I.M., Nisula B.C., Cutler G.B. et al.: "Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486". J. Clin. Endocrinol. Metab., 1985, 61, 536.
40. Chrousos G.P., Laue L., Nieman L.K., Kawai S., Udelsman R.U., Brandon D.D. et al.: "Glucocorticoids and glucocorticoid antagonists: lessons from RU 486". Kidney Int. Suppl., 1988, 26, S18.
41. Chu J.W., Matthias D.F., Belanoff J., Schatzberg A., Hoffman A.R., Feldman D.: "Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)". J. Clin. Endocrinol. Metab., 2001, 86, 3568.